DERMAVANT HOLDINGS LIMITED

• ◆

  Material uncertainty over going concern

  The circumstances described above, including scenarios where there is a change in the group cash pooling arrangements and uncertainty over whether equivalent financial support will remain available following the potential change in ownership, indicate the existence of a material uncertainty

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

• ·

  Going-concern uncertainty disclosed

Figures converted to GBP from USD at 0.742 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. Year-on-year comparison hidden: this filing covers about 12 months versus 9 months prior. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The circumstances described above, including scenarios where there is a change in the group cash pooling arrangements and uncertainty over whether equivalent financial support will remain available following the potential change in ownership, indicate the existence of a material uncertainty”

Group structure

1. DERMAVANT HOLDINGS LIMITED · parent
   1. Dermavant Sciences GmbH 100% · Switzerland · Manufacture and sale of pharmaceutical products
   2. Dermavant Sciences IRL Limited 100% · Ireland · Non-trading entity

Significant events

• “During the prior year, on 28 October 2024, the Company, along with its subsidiaries and immediate parent, Dermavant Sciences Limited, were acquired by Organon & Co. As a result, the Company is now part of the Organon Group.”
• “On 12 December 2025, a special resolution was passed for Dermavant Sciences IRL that the company would be voluntarily liquidated, and that Grant Thornton would be appointed as liquidators.”
• “On 26 April 2026, Organon & Co. announced a definitive agreement under which Sun Pharmaceutical Industries Limited will acquire all outstanding shares of Organon & Co. for US$ 14.00 per share with an enterprise valuation of US$ 11.75 billion.”
• “On 29 May 2026, Dermavant Sciences Ltd (DSL) repaid the principal amount of the intercompany loan of $86,000 and all accrued interest. Subsequently, the directors of DHL declared and paid an interim cash dividend of $92,000 to DSL.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.